Information for Healthcare Providers
Q fever is a disease with acute and chronic presentations caused by the bacterium Coxiella burnetii. Cattle, sheep, and goats are the primary reservoirs, although a variety of species may be infected. Organisms are excreted in milk, urine, and feces of infected animals with the highest numbers shed during birthing in the amniotic fluids and the placenta. The organism is extremely hardy and resistant to heat, drying, and many common disinfectants, which enable the bacteria to survive for long periods in the environment. Exposure usually occurs by inhalation of these organisms from air that is contaminated by excreta of infected animals. Other modes of transmission, including tick bites, ingestion of unpasteurized milk or dairy products, and person-to-person transmission, are rare. People are very susceptible to the disease, and very few organisms may be required to cause infection.
Q fever can cause acute or chronic illness, and people are commonly exposed from contact with infected animals or exposure to contaminated environments. The acute symptoms usually develop within 2-3 weeks of exposure, although as many as half of infected people are asymptomatic.
The following is a list of symptoms commonly seen with acute Q fever. However, it is important to note that the combination of signs and symptoms vary greatly from person to person.
- High fever (up to 105°F)
- Severe headache
- General malaise
- Chills or sweats
- Non-productive cough
- Abdominal pain
- Chest pain
Most people with acute Q fever infection recover completely; however, some may experience serious illness with pneumonia, granulomatous hepatitis, myocarditis, or central nervous system complications.
Pregnant women who are infected (even without clinical illness) may be at risk for miscarriage, stillbirth, pre-term delivery, or low infant birth weight.
Clinical course. Treatment with doxycycline will shorten the course of illness for acute Q fever. Although the majority of people with acute Q fever recover completely, a post-Q fever fatigue syndrome has been reported to occur in up to 20% of patients with acute Q fever. This syndrome is characterized by constant or recurring fatigue, night sweats, severe headaches, photophobia, pain in muscles and joints, mood changes, and difficulty sleeping. No consensus has been reached in the medical community on the pathogenesis or treatment of post Q fever fatigue syndrome.
Chronic Q fever occurs in <5% of acutely infected patients. It may present within weeks after an acute infection or may manifest many years later. Anyone who was infected with C. burnetii may be at risk for developing chronic Q fever, however, people with a history of valvular defects, arterial aneurisms, or vascular grafts are at increased risk. Women infected by C. burnetii during pregnancy and those with immunosuppression have also been linked to the development of chronic Q fever.
Endocarditis is the most commonly identified manifestation of chronic Q fever and is fatal if untreated. Patients with endocarditis require early diagnosis and long-term antibiotic treatment (at least 18 months) for a successful outcome. Other forms of chronic Q fever include infections of vascular aneurysms, bone, liver, or reproductive organs.
Several aspects of Q fever make it challenging for healthcare providers to diagnose and treat. The symptoms vary from patient to patient and can be difficult to distinguish from other diseases. Diagnostic tests based on the detection of antibodies will frequently appear negative in the first 7-15 days of illness. For this reason, healthcare providers must treat patients based on clinical suspicion alone and not wait for the return of confirmatory tests. Detection of C. burnetii DNA by polymerase chain reaction (PCR) can rapidly confirm an acute Q fever infection. Samples are ideally taken during the first 2 weeks of illness and before or shortly following doxycycline administration. For definitive diagnosis in the early stages of illness it is recommended to use serologic tests in combination with PCR of whole blood or serum. Treatment should be initiated as soon as Q fever is suspected and should never be withheld pending the receipt of diagnostic test results.
Patient history. Information such as recent travel to rural or agricultural communities where infected livestock may be present, or employment in high-risk occupations, such as veterinarians or farmers, can be helpful in making the diagnosis. Chronic Q fever is a risk for anyone with a history of acute Q fever, but are more frequent in persons with valvular disease, blood vessel abnormalities, immunosuppressed persons, and women who were pregnant when they became infected. Persons with these risk factors should be routinely monitored using serologic methods for the 2 years following diagnosis of acute Q fever to ensure rapid diagnosis and treatment of chronic Q fever.
Other clinical evidence. Healthcare providers should also look at routine blood tests, such as a complete blood cell count or a chemistry panel. Clues such as a prolonged fever with low platelet count, normal leukocyte count, and elevated liver enzymes are suggestive of acute Q fever infection, but may not be present in all patients. After a suspect diagnosis is made based on clinical suspicion and treatment has begun, specialized laboratory testing should be used to confirm the diagnosis of Q fever.
Diagnosis of Acute Q fever
Chronic Q fever is confirmed by elevated phase I IgG antibody >1:1024 (and is typically higher than phase II IgG) and an identifiable persistent focus of infection (e.g., endocarditis). Whole blood, serum or tissue biopsies may be tested by PCR for C. burnetii. PCR of whole blood has low sensitivity in patients with chronic Q fever endocarditis, so serum antibody titers should also be tested. PCR or immunohistochemistry of biopsy specimens from the site of active infection has also been used to diagnose chronic Q fever. These tests may be appropriate for endocarditis patients undergoing valve replacement surgery or patients with hepatitis.
For more in-depth information about the diagnosis of Q fever, please see the diagnostic section in the MMWR Diagnosis and Management of Q fever—United States, 2013.
For information on submitting a sample to CDC for testing, please see Information for Public Health Officials.
Doxycycline is the recommended first-line treatment for non-pregnant adults with Q fever and is most effective at preventing severe complications if it is started within the first 3 days of symptoms. Treatment must be based on clinical suspicion and should always begin before laboratory results return. If the patient is treated within the first 3 days of the disease, fever generally subsides within 72 hours. Severely ill patients may require longer periods before their fever resolves.
Treatment is generally not recommended for patients who are asymptomatic or who have already recovered from their illness, but might be considered for those at high risk of developing chronic Q fever. There is no role for prophylactic antimicrobial agents in preventing Q fever after a known, naturally occurring exposure and prior to symptom onset; attempts at prophylaxis will likely extend the incubation period by several days but will not prevent infection from occurring.
Recommended Treatment and Dosage for Acute Q Fever
- Adults: Doxycycline, 100 mg every 12 hours for 14 days
- Pregnant women: trimethoprim/sulfamethoxazole, 160 mg/800 mg given twice a day throughout pregnancy, but not beyond 32 weeks gestation
- Children 8 years or older: doxycycline, 2.2 mg/kg body weight (up to 100mg) given twice a day for 14 days
- Children under 8 years with high risk criteria (i.e., those that are hospitalized, have severe illness, preexisting heart valvulopathy, immunocompromised, or delayed treatment for Q fever > 2 weeks): doxycycline, 2.2 mg/kg body weight (up to 100 mg) given twice a day for 14 days
- Children under 8 years with mild or uncomplicated illness: doxycycline, 2.2 mg/kg body weight (up to 100 mg) given twice a day for 5 days. If patient remains febrile past 5 days of treatment, treat with trimethoprim/sulfamethoxazole 4-20 mg/kg/24 hours (dose based on trimethoprim component) in equally divided doses every 12 hours (maximum: 320 mg trimethoprim per 24 hours).
Recommended Treatment and Dosage for Chronic Q Fever
Duration of treatment for chronic Q fever is based on serologic response and evidence of clinical improvement. Serologic monitoring of a patient with chronic Q fever should be done in consultation with an infectious disease specialist.
- Adults with endocarditis or vascular infection: doxycycline, 100 mg every 12 hours and hydroxychloroquine, 200 mg every 8 hours, for at least 18 months.
- Adults with non-cardiac organ disease: doxycycline, 100 mg every 12 hours and hydroxychloroquine, 200 mg every 8 hours.
- Postpartum women with titers elevated >12 months after delivery: doxycycline, 100 mg every 12 hours and hydroxychloroquine, 200 mg every 8 hours for 12 months.
- Pregnant women: no current recommendations. Consultation with an infectious disease and obstetric specialist is encouraged.
- Children: no current recommendations. Consultation with a pediatric infectious disease specialist is encouraged.
Doxycycline and Children
Short course therapy (e.g., <5 days) with doxycycline does not cause staining of permanent teeth, and most experts consider the benefit of doxycycline in treating Q fever greater than the potential risk of dental staining. Children with mild illness who are less than 8 years of age may be treated with a shorter dose (5 days) of doxycycline to minimize their exposure to the medication. Children with preexisting cardiac valve disease, or who are immunocompromised, or have delayed Q fever diagnosis and have experienced illness for 2 weeks without resolution of symptoms are considered to be at high risk for developing severe disease and should be treated with doxycycline for 2 weeks.
People with life-threatening allergies to doxycycline may need to consider alternate antibiotics such as moxifloxacin, clarithromycin, trimethoprim/sulfamethoxazole and rifampin.
For more in-depth information about the treatment and management of Q fever, please see the treatment and management section in the MMWR Diagnosis and Management of Q fever—United States, 2013.
- C. burnetii is a highly infectious agent that is resistant to heat, drying, and many common disinfectants.
- It can be aerosolized and inhalation is the primary route of infection for people.
- As few as 1-10 C. burnetii organisms may cause disease in a susceptible person.
- This agent has been previously weaponized for use in biological warfare and is considered a potential terrorist threat.
- The World Health Organization has estimated that if 50 kg of C. burnetii were aerosolized over an urban area with 500,000 inhabitants, there would be 125,000 cases of acute illness, 9,000 cases of chronic Q fever, and 150 fatalities (Health aspects of chemical and biological weapons, 1st edition, 1970).
- Person to person transmission is possible via transplacental exposure, sexual contact, blood transfusion, and transplantation.
- Nosocomial infections have been rarely reported following autopsies and obstetrical procedures involving infected persons. (For more information on Occupational Exposure and Prevention relating to Q fever see the CDC’s MMWR Diagnosis and Management of Q fever—United States, 2013)
- Clusters of pneumonia, or unusual clusters of acute febrile illness with respiratory involvement or granulomatous hepatitis, in a community where no other cause can be identified may indicate a possible intentional release of C. burnetii.
- In cases of suspected intentional release, post exposure prophylaxis (doxycycline 100 mg twice a day for 5-7 days) can be considered in groups determined to be at high risk for exposure, but is not recommended for the prevention of naturally occurring Q fever. Chemoprophylaxis is only considered effective if administered within 8-12 days of exposure.
- Page last reviewed: December 26, 2017
- Page last updated: December 26, 2017
- Content source: